GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aurinia Pharmaceuticals Inc (NAS:AUPH) » Definitions » Shiller PE Ratio

Aurinia Pharmaceuticals (Aurinia Pharmaceuticals) Shiller PE Ratio : (As of May. 26, 2024)


View and export this data going back to 2009. Start your Free Trial

What is Aurinia Pharmaceuticals Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Aurinia Pharmaceuticals Shiller PE Ratio Historical Data

The historical data trend for Aurinia Pharmaceuticals's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aurinia Pharmaceuticals Shiller PE Ratio Chart

Aurinia Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Aurinia Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Aurinia Pharmaceuticals's Shiller PE Ratio

For the Biotechnology subindustry, Aurinia Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aurinia Pharmaceuticals's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aurinia Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Aurinia Pharmaceuticals's Shiller PE Ratio falls into.



Aurinia Pharmaceuticals Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Aurinia Pharmaceuticals's E10 for the quarter that ended in Mar. 2024 is calculated as:

For example, Aurinia Pharmaceuticals's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.07/126.2576*126.2576
=-0.070

Current CPI (Mar. 2024) = 126.2576.

Aurinia Pharmaceuticals Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201406 -0.350 99.473 -0.444
201409 0.080 99.394 0.102
201412 -0.210 98.367 -0.270
201503 -0.270 99.789 -0.342
201506 -0.020 100.500 -0.025
201509 -0.160 100.421 -0.201
201512 -0.130 99.947 -0.164
201603 -0.130 101.054 -0.162
201606 -0.100 102.002 -0.124
201609 -0.210 101.765 -0.261
201612 -0.220 101.449 -0.274
201703 -0.920 102.634 -1.132
201706 -0.030 103.029 -0.037
201709 -0.160 103.345 -0.195
201712 -0.040 103.345 -0.049
201803 -0.180 105.004 -0.216
201806 -0.190 105.557 -0.227
201809 -0.210 105.636 -0.251
201812 -0.170 105.399 -0.204
201903 -0.140 106.979 -0.165
201906 -0.170 107.690 -0.199
201909 -0.210 107.611 -0.246
201912 -0.780 107.769 -0.914
202003 -0.230 107.927 -0.269
202006 -0.240 108.401 -0.280
202009 -0.340 108.164 -0.397
202012 -0.050 108.559 -0.058
202103 -0.400 110.298 -0.458
202106 -0.370 111.720 -0.418
202109 -0.390 112.905 -0.436
202112 -0.250 113.774 -0.277
202203 -0.270 117.646 -0.290
202206 -0.250 120.806 -0.261
202209 -0.060 120.648 -0.063
202212 -0.180 120.964 -0.188
202303 -0.180 122.702 -0.185
202306 -0.080 124.203 -0.081
202309 -0.090 125.230 -0.091
202312 -0.180 125.072 -0.182
202403 -0.070 126.258 -0.070

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Aurinia Pharmaceuticals  (NAS:AUPH) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Aurinia Pharmaceuticals Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Aurinia Pharmaceuticals's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Aurinia Pharmaceuticals (Aurinia Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
4464 Markham Street, Suite 1203, Victoria, BC, CAN, V8Z 7X8
Aurinia Pharmaceuticals Inc is a biopharmaceutical company. It provides products for patients suffering from serious diseases with a high unmet medical need. The firm is developing LUPKYNIS (voclosporin), an investigational drug, for the treatment of lupus nephritis (LN), focal segmental glomerulosclerosis (FSGS), and Dry Eye Syndrome (DES). Geographically, it derives maximum revenue from the United States.
Executives
Robert T Foster director C/O CONTRAVIR PHARMACEUTICALS, INC., 399 THORNALL STREET, FIRST FLOOR, EDISON NJ 08837
Karen L. Smith director C/O JAZZ PHARMACEUTICALS PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN L2 4 L2
Jeffrey Allen Bailey director BIODELIVERY SCIENCES INTERNATIONAL, INC., 4131 PARKLAKE AVE., SUITE 225, RALEIGH NC 27612
R. Hector Mackay-dunn director #1203-4464 MARKHAM STREET, VICTORIA A1 V8Z7X8
Jayne David R.w. director #1203-4464 MARKHAM STREET, VICTORIA A1 BC V8Z7X8
Jill Leversage director #1203-4464 MARKHAM STREET, VICTORIA A1 V8Z 7X8
Daniel Billen director #1203-4464 MARKHAM STREET, VICTORIA A1 V8Z 7X8
Joseph P Hagan director 3344 N. TORREY PINES COURT, SUITE 200, LA JOLLA CA 92037
Brinda Balakrishnan director #1203-4464 MARKHAM STREET, VICTORIA A1 V8Z7X8
Peter Greenleaf director, officer: Chief Executive Officer ONE MEDIMMUNE WAY, GAITHERSBURG MD 20878
Joseph M Miller officer: Chief Financial Officer C/O CERECOR INC., 400 EAST PRATT STREET, SUITE 606, BALTIMORE MD 21202
Stephen P. Robertson officer: EVP, General Counsel #1203-4464 MARKHAM STREET, VICTORIA A1 BC V8Z7X8
Milne George M Jr director
Matthew Maxwell Donley officer: Ex VP, Intern'l Operations 4520 EAST WEST HIGHWAY, 3RD FLOOR, BETHESDA MD 20814
Scott Michael Habig officer: Chief Commercial Officer #1203-4464 MARKHAM STREET, VICTORIA A1 V8Z7X8

Aurinia Pharmaceuticals (Aurinia Pharmaceuticals) Headlines

From GuruFocus

Aurinia Announces 2023 Annual General Meeting Results

By Business Wire Business Wire 05-17-2023